Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2193]

IORT at University Hospital Augsburg in Germany

Dr Klaus-Henning Kahl - University Hospital Augsburg, Augsburg, Germany

IORT at University Hospital Augsburg in Germany ( Dr Klaus-Henning Kahl - University Hospital Augsburg, Augsburg, Germany )

Raising awareness of the burden of cervical cancer in the Eastern Mediterranean...

Dr Ibtihal Fadhil - Eastern mediterranean NCD Alliance, Kuwait City, Kuwait

Raising awareness of the burden of cervical cancer in the Eastern Mediterranean region ( Dr Ibtihal Fadhil - Eastern mediterranean NCD Alliance, Kuwait City, Kuwait )

Improving access to palliative care by enhancing primary care services in an...

Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia

Improving access to palliative care by enhancing primary care services in an upper middle-income country ( Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia )

Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows...

Dr Daniel Geynisman - Fox Chase Cancer Center, Pennsylvania, USA

Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC ( Dr Daniel Geynisman - Fox Chase Cancer Center, Pennsylvania, USA )

Pembrolizumab shows notable antitumour activity for patients with high-risk...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer